Checkpoint inhibitors show encouraging activity in patients with chemo-naïve mCRPC

While checkpoint inhibitors have revolutionized the treatment of many solid tumor types, such as malignant melanoma, lung cancer, and renal cell carcinoma, the response rate in prostate cancer as monotherapy has been low. Several PDL1 inhibitors are now being evaluated in combination with docetaxel in mCRPC and there appears to be synergy.